Ironwood Q1 revenue down 28% YoY, net loss $4.2M; apraglutide Phase III positive

IRONWOOD PHARMACEUTICALS INC

2024-Q1 EPS reported -$0.03 revenue$74,877,000

Q1 total revenue $74.9M vs $104.1M YoY; GAAP net loss of $4.2M vs net income of $45.7M.
LINZESS prescription demand grew 10% YoY; revenue impacted by gross-to-net change.
Positive Phase III STARS trial of apraglutide in SBS-IF; NDA filing planned.
Revised FY 2024 guidance due to LINZESS gross-to-net change estimate.
Adjusted EBITDA fell to $12.8M from $60.4M YoY; non-GAAP net loss per share $(0.02).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRONWOOD PHARMACEUTICALS INC reported first quarter 2024 results: revenue $74,877, net income $(4,162), EPS $(0.03).

Period: first quarter 2024
Revenue: $74,877
Net income: $(4,162)
EPS: $(0.03)
Result: reported results

Exact text from the filing

growth, and delivering sustained profits and cash flow.” First Quarter 2024 Financial Highlights 1 (in thousands, except for per share amounts) Q1 2024 Q1 2023 Total revenue 2 $ 74,877 $ 104,061 Total operating expenses 63,857 43,964 GAAP net income (loss) 2 (4,162 ) 45,714 GAAP net income (loss) – per share basic 2 (0.03 ) 0.30 GAAP net income (loss) – per

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-059101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.